Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	370
Overall Study	STARTED	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	366
Overall Study	STARTED	Placebo Plus Taxane and Carboplatin	364
Overall Study	Safety Analysis Set	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	376
Overall Study	Safety Analysis Set	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	363
Overall Study	Safety Analysis Set	Placebo Plus Taxane and Carboplatin	352
Overall Study	COMPLETED	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	0
Overall Study	COMPLETED	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	0
Overall Study	COMPLETED	Placebo Plus Taxane and Carboplatin	0
Overall Study	NOT COMPLETED	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	370
Overall Study	NOT COMPLETED	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	366
Overall Study	NOT COMPLETED	Placebo Plus Taxane and Carboplatin	364

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00849667/flow